Description: Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Home Page: www.championsoncology.com
One University Plaza
Hackensack,
NJ
07601
United States
Phone:
201 808 8400
Officers
| Name | Title |
|---|---|
| Dr. Ronnie Morris M.D. | CEO & Director |
| Mr. David Barry Miller M.B.A. | Chief Financial Officer |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer |
| Mr. Arthur Hanson | Vice President of Technology |
| Ms. Rachel A. Bunting M.B.A., M.S., MBA, MS | Vice President of Global Marketing |
| Dr. Michael Ritchie M.B.A., Ph.D. | Chief Commercial Officer |
| Dr. Karin Abarca Heidemann Ph.D. | Executive Vice President of Global Scientific Operations |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services & Partnering |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 22.3214 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.6027 |
| Price-to-Sales TTM: | 1.0865 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 210 |